Home » Stocks » SGEN

Seagen, Inc. (SGEN)

Stock Price: $165.89 USD -2.18 (-1.30%)
Updated November 24, 12:43 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 29.91B
Revenue (ttm) 1.86B
Net Income (ttm) 472.41M
Shares Out 180.31M
EPS (ttm) 2.65
PE Ratio 62.60
Forward PE 625.00
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $165.89
Previous Close $168.07
Change ($) -2.18
Change (%) -1.30%
Day's Open 167.82
Day's Range 164.40 - 168.38
Day's Volume 305,126
52-Week Range 90.57 - 213.94

More Stats

Market Cap 29.91B
Enterprise Value 28.26B
Earnings Date (est) Feb 11, 2021
Ex-Dividend Date n/a
Shares Outstanding 180.31M
Float 178.35M
EPS (basic) 2.72
EPS (diluted) 2.65
FCF / Share 3.27
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.60%
FCF Yield 1.91%
Payout Ratio n/a
Shares Short 3.50M
Short Ratio 4.24
Short % of Float 1.96%
Beta 1.20
PE Ratio 62.60
Forward PE 625.00
P/FCF Ratio 52.41
PS Ratio 16.05
PB Ratio 13.75
Revenue 1.86B
Operating Income 393.45M
Net Income 472.41M
Free Cash Flow 570.68M
Net Cash 1.65B
Net Cash / Share 9.17
Gross Margin 8.23%
Operating Margin 21.11%
Profit Margin 25.30%
FCF Margin 30.62%
ROA 9.64%
ROE 23.40%
ROIC 37.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (20)

Buy 12
Overweight 0
Hold 7
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$201.94*
(21.73% upside)
Low
165
Current: $165.89
High
254
Target: 201.94
*Average 12-month price target from 17 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue91765548241833728726921194.78107
Revenue Growth40.02%35.76%15.33%24.15%17.45%6.5%27.73%122.43%-11.81%-
Gross Profit87356642837629925824819791.66107
Operating Income-221-260-196-143-121-77.36-62.86-57.25-144-68.20
Net Income-159-223-126-140-120-76.14-62.52-53.78-152-66.27
Shares Outstanding165158143141129123122118113101
Earnings Per Share-0.96-1.41-0.88-1.00-0.93-0.62-0.51-0.46-1.34-0.66
Operating Cash Flow-164-204-119-96.97-133-60.00-1.1110.88-1246.81
Capital Expenditures-70.75-21.22-70.38-27.84-13.39-17.18-22.15-10.49-11.25-3.55
Free Cash Flow-234-225-189-125-147-77.18-23.260.40-1353.26
Cash & Equivalents811411413589650313374364331282
Total Debt67.61---------
Net Cash / Debt743411413589650313374364331282
Assets2,2061,503878838895459484471425330
Liabilities330229200204209248254245206168
Book Value1,8761,274678634686211230226219162
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Seagen, Inc.
Country United States
Employees 1,605
CEO Clay B. Siegall

Stock Information

Ticker Symbol SGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SGEN

Description

Seagen, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.